Molecular biological determinations of meningioma progression and recurrence

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Linsler, Stefan ^a   Kraemer, Dennis ^a   Driess, Christina ^a   Oertel, Joachim ^a   Kammers, Kai ^b,c   Rahnenführer, Jörg ^b   Ketter, Ralf ^a   Urbschat, Steffi ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME DELETION 1P; CHROMOSOME MUTATION; DISEASE COURSE; DISEASE MARKER; DNA METHYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; TIMP3 GENE; TUMOR SUPPRESSOR GENE; AGED; CANCER GRADING; CHROMOSOME 1; CHROMOSOME ABERRATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGION; TUMOR RECURRENCE;

TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84899521495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094987     Document Type: Article

References (59)

1. Beks JW, de Windt HL (1988) The recurrence of supratentorial meningiomas after surgery. Acta Neurochir (Wien) 95:3-5. (Pubitemid 19015594)
2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225; discussion 226-219.
3. Ketter R, Urbschat S, Henn W, Feiden W, Beerenwinkel N, et al. (2007a) Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. Int J Cancer 121:1473-1480. (Pubitemid 47328705)
4. Ketter R, Kim YJ, Storck S, Rahnenfuhrer J, Romeike BF, et al. (2007b) Hyperdiploidy defines a distinct cytogenetic entity of meningiomas. J Neurooncol 83:213-221. (Pubitemid 46784996)
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. (Pubitemid 47103521)
6. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, et al. (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827-832.
7. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP (1993) Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43:2096-2098. (Pubitemid 23318886)
8. Zang KD. (2001) Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 93:207-220.
9. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20:623-631.
10. Stuart MA, Lusis EA, Scheck AC, Coons MD, Lal AL, et al. (2013) Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol, PMC2013 November 25.
11. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, et al. (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798-802. (Pubitemid 29086729)
12. Bai YX, Yi JL, Li JF, Sui H (2007) Clinicopathologic significance of BAG1 and TIMP3 expression in colon carcinoma. World J Gastroenterol 13:3883-3885.
13. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, et al. (2005) Frequent LOH on 22q12.3 and TIMP3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85:165-175. (Pubitemid 40208920)
14. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, et al. (2008) Quantitative detection of TIMP3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep 20:1489-1495.
15. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, et al. (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835-1839. (Pubitemid 30207640)
16. Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, et al. (2012) MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol 107:617-631.
17. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, et al. (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669. (Pubitemid 32751096)
18. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, et al. (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55:149-158. (Pubitemid 34134038)
19. Ishino S, Hashimoto N, Fushiki S, Date K, Mori T, et al. (1998) Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer Jul 15;83(2):360-6.
20. Mawrin C, Perry A (2010). Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379-391.
21. Muller P, Henn W, Niedermayer I, Ketter R, Feiden W, et al. (1999) Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 5:3569-3577.
22. Niedermayer I, Kolles H, Zang KD, Feiden W (1996). Characterization of intermediate type (WHO "atypical") meningiomas. Clin Neuropathol 15:330-336. (Pubitemid 26380227)
23. Sayagues JM, Tabernero MD, Maillo A, Diaz P, Rasillo A, et al. (2002) Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry 50:153-159. (Pubitemid 37517314)
24. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, et al. (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55:149-158. (Pubitemid 34134038)
25. Zang KD, Singer H. (1967) Chromosomal consitution of meningiomas. Nature 216:84-85.
26. Zang KD, Singer H (1968) The cytogenetics of human tumors. Angew Chem Int Ed Engl 7:709-718.
27. Zang KD (1982) Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6:249-274.
28. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, et al. (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9:296-298. (Pubitemid 24114835)
29. Henn W, Cremerius U, Heide G, Lippitz B, Schroder JM, et al. (1995) Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 79:144-148.
30. Ketter R, Henn W, Niedermayer I, Steilen-Gimbel H, Konig J, et al. (2001) Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 95:601-607. (Pubitemid 33031421)
31. Ketter R, Rahnenfuhrer J, Henn W, Kim YJ, Feiden W, et al. (2008) Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery 62:61-69; discussion 69-70.
32. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, et al. (1997) Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 56:879-886. (Pubitemid 27329109)
33. Urbschat S, Rahnenfuhrer J, Henn W, Feiden W, Wemmert S, et al. (2011) Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence. Int J Oncol 39:1601-1608.
34. Deodhar K, Gheit T, Vaccarella S, Romao CC, Tenet V, et al. (2012) Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol 84:1054-1060.
35. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799. (Pubitemid 39070849)
36. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692.
37. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, et al. (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133. (Pubitemid 30058742)
38. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, et al. (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
39. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, et al. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837-841. (Pubitemid 27098005)
40. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
41. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, et al. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756. (Pubitemid 24153417)
42. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115-177. (Pubitemid 28530512)
43. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22-39.
44. Perry A, Stafford SL, Scheidhauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21: 1455-1465. (Pubitemid 27528256)
45. Perry A, Scheithauer BW, Stafford SL, Lohse CM Wollan PC (1999) "Malignancy" in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer 85: 2046-2056. (Pubitemid 29202781)
46. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of tumours of the central nervous system. WHO Classification of tumours of the central nervous system. IARC, Lyon.
47. Hopman AH, Ramaekers FC, Raap AK, Beck JL, Devilee P, et al. (1988) In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 89:307-316.
48. Muellenbach R, Lagoda PJ, Welter C (1989) An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. Dec;5(12):391.
49. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826. (Pubitemid 26296693)
50. Righini CA, de Fraipont F, Reyt E, Favrot MC (2007) Aberrant methylation of tumor suppressor genes in head and neck squamous cell carcinoma: is it clinically relevant? Bull Cancer 94:191-197. (Pubitemid 46456113)
51. Muhlisch J, Bajanowski T, Rickert CH, Roggendorf W, Wurthwein G, et al. (2007) Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 83:17-29. (Pubitemid 46647160)
52. Al-Mefty O, Paulo A, Kadri S, Svetlana P, Jeffery RS, et al. (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210-218. (Pubitemid 38970995)
53. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, et al. (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714-723. (Pubitemid 47106199)
54. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, et al. (2004). DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108:413-421. (Pubitemid 39462353)
55. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, et al. (2005) Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42:314-319. (Pubitemid 40171195)
56. van Tilborg AA, Morolli B, Giphart-Gassler M, de Vries A, van Geenen DA, et al. (2006) Lack of genetic and epigenetic changes in meningiomas without NF2 loss. J Pathol 208:564-573. (Pubitemid 43329343)
57. Liu Y, Pang JC, Dong S, Mao B, Poon WS, et al. (2005) Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416-425. (Pubitemid 40591813)
58. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW (1996) Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Cancer 77:2567-2573. (Pubitemid 26169154)
59. Perry A, Gutmann DH, Reifenberger G (2004). Molecular pathogenesis of meningiomas. J Neurooncol Nov; 70(2):183-202.